Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 ‘CREATE’-Reference-Cited by-同舟云学术

Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 ‘CREATE’

Published:2017-12 Issue:12 Volume:28 Page:3000-3008
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Schöffski P.,Wozniak A.,Stacchiotti S.,Rutkowski P.,Blay J.-Y.,Lindner L.H.,Strauss S.J.,Anthoney A.,Duffaud F.,Richter S.,Grünwald V.,Leahy M.G.,Reichardt P.,Sufliarsky J.,van der Graaf W.T.,Sciot R.,Debiec-Rychter M.,van Cann T.,Marréaud S.,Lia M.,Raveloarivahy T.,Collette L.,Bauer S.

Funder

National Institutes of Health

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/28/12/3000/24169148/mdx527.pdf

Reference20 articles.

1. Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas;Van Glabbeke;Eur J Cancer,2002

2. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial;van der Graaf;Lancet,2012

3. Identification of the receptor tyrosine kinase c-Met and its ligand, Hepatocyte Growth Factor, as therapeutic targets in clear cell. Sarcoma;Davis;Cancer Res,2010